SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
SCYNEXIS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.66−0.01 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $43.28M
- P/E (TTM)
- –
- Dividend yield
- –
SCYNEXIS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Agreement Revenue | $17.77M | $18.90M | $19.16M | $2.93M | $3.26M | $2.63M | $3.75M | $8.51M | $10.22M | $140.47M | $139.10M | $133.46M | 92.5% | +445.5% |
| Product Revenue, Net | – | – | – | – | – | – | $0 | $60.00K | -$554.00K | -$86.00K | $1.04M | $2.41M | – | – |
By region
From the segment and revenue-disaggregation notes of Scynexis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.